Cargando…

Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476753/ https://www.ncbi.nlm.nih.gov/pubmed/26098116 http://dx.doi.org/10.1371/journal.pone.0131264

Ejemplares similares

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
por: De Rosa, Francesco G., et al.
Publicado: (2015)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
por: Moreno-García, E, et al.
Publicado: (2022)

2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)

Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
por: Moreno-García, E, et al.
Publicado: (2021)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible Common Candida Species: A Propensity Score Matching Analysis
por: Kim, Jong Hun, et al.
Publicado: (2023)

Outcomes Comparing Initial Short vs Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains
por: Small-Saunders, Jennifer L, et al.
Publicado: (2017)

146 Review of Empiric Echinocandin Therapy for Candidemia
por: Amado, Cristina, et al.
Publicado: (2014)

Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment
por: Lausch, Karen Rokkedal, et al.
Publicado: (2018)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

The Diagnostic Relevance of β-D-Glucan for Candidemia within Internal Medicine Wards
por: Corcione, Silvia, et al.
Publicado: (2022)

Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU
por: Daneshnia, Farnaz, et al.
Publicado: (2022)

Impact of echinocandins as first-choice therapy in cardiothoracic high-risk patients with candidemia
por: Langebartels, G, et al.
Publicado: (2013)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007
por: Poikonen, Eira, et al.
Publicado: (2010)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia
por: Tantasuwan, Suchavadee, et al.
Publicado: (2022)

Candidemia in non-ICU surgical wards: Comparison with medical wards
por: Vena, Antonio, et al.
Publicado: (2017)

Correction to: Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry
por: Corrao, Salvatore, et al.
Publicado: (2021)

The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
por: Tóth, Zoltán, et al.
Publicado: (2022)

Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance
por: Grosset, Marine, et al.
Publicado: (2016)

2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis
por: Demir, Koray K, et al.
Publicado: (2019)

Correction to: Procalcitonin levels in candidemia versus bacteremia: a systematic review
por: Cortegiani, Andrea, et al.
Publicado: (2019)

Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria
por: Biagi, Mark J, et al.
Publicado: (2019)

Candidemia in Internal Medicine: Facing the New Challenge
por: Brescini, Lucia, et al.
Publicado: (2022)

Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit
por: Pinhati, Henrique Marconi Sampaio, et al.
Publicado: (2016)

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era
por: Routsi, Christina, et al.
Publicado: (2022)

Incidence of candidemia before and after fluconazole prophylaxis implementation in a 14-bed general ICU
por: Vartzeli, P, et al.
Publicado: (2008)

Correction: Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China
por: Li, Yi, et al.
Publicado: (2023)

Correction to: Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2018)

468. Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
por: Lodise, Thomas, et al.
Publicado: (2022)

Evaluation of the early fluconazole treatment of candidemia protocol with automated short message service alerts: a before-and-after study
por: Yoo, Jeong Rae, et al.
Publicado: (2021)

Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation
por: Zilberberg, Marya D, et al.
Publicado: (2009)

Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait
por: Al-Baqsami, Zahraa F., et al.
Publicado: (2020)

Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak
por: Szekely, Jidapa, et al.
Publicado: (2023)

Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India
por: Sharma, Cheshta, et al.
Publicado: (2015)

A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-Resistant Candida parapsilosis in the COVID-19 Era
por: Thomaz, Danilo Y., et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis
por: Ramos-Martínez, Antonio, et al.
Publicado: (2022)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0f06cqne2qbjs3099oogivfm74